The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: A retrospective analysis
OncoTargets and Therapy May 04, 2018
Wang LL, et al. - In a real-life setting, the efficacy of combination icotinib and chemotherapy was compared to that of icotinib or chemotherapy alone in untreated non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)-sensitive mutations. Additionally, the curative impact of different treatments on different genetic mutations (EGFR 19 exon deletion and L858R mutation) was analyzed in this retrospective analysis. Improved progression free survival and overall survival were achieved with combination icotinib and chemotherapy in patients with untreated NSCLC harboring sensitive EGFR mutations, particularly in those who harbored the EGFR exon 19 deletion.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries